{
  "patent_number": "US 12630603",
  "country": "US",
  "title": "Making Better CAR-T Cells to Fight Lymphoma",
  "original_title": "Chimeric antigen receptor T cell therapy",
  "summary": "This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain \"naïve\" T cells to improve treatment success and reduce side effects.",
  "what_it_does": "The patent claims a method for making an anti-CD19 Chimeric Antigen Receptor (CAR)-T cell immunotherapy product that works better and has fewer severe side effects for Non-Hodgkin's Lymphoma (NHL) patients. It involves taking a patient's T cells and, during the manufacturing process, specifically increasing or maximizing the percentage of \"naïve\" CD4+ and CD8+ T cells, identified by the CD45RA+ CCR7+ markers (Claim 1). This optimized product must contain at least 20x10^6 of these specific naïve T cells, adjusted for the patient's tumor size (Claim 1). For example, a patient with relapsed/refractory large B-cell lymphoma (Claim 3) would receive a CAR-T infusion engineered with a higher proportion of these specific T cells, aiming for a more lasting response and less severe cytokine release syndrome or neurological issues (Claim 1).",
  "what_it_does_not_cover": [
    "Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (Claim 1).",
    "Does not cover CAR-T cell manufacturing methods that do not ensure at least 20x10^6 of these specific naïve T cells in the final product (Claim 1).",
    "Does not cover CAR-T cell therapies targeting antigens other than CD19 (Claim 1).",
    "Does not cover CAR-T cell therapies for cancers other than Non-Hodgkin's Lymphoma, advanced-stage indolent NHL, large B-cell lymphoma, or Mantle Cell Lymphoma (Claim 3).",
    "Does not cover methods of simply administering CAR-T cells without a specific manufacturing step to enrich for naïve T cells."
  ],
  "filed": "2021-02-20",
  "granted": "2026-05-19",
  "expires": "2041-02-20",
  "status": "active",
  "holder": "Kite Pharma",
  "holder_url": "https://patentbrief.org/company/kite-pharma",
  "inventors": [
    {
      "name": "John Rossi",
      "url": "https://patentbrief.org/inventor/john-rossi"
    },
    {
      "name": "Jenny Jiyun Kim",
      "url": "https://patentbrief.org/inventor/jenny-jiyun-kim"
    },
    {
      "name": "Adrian Bot",
      "url": "https://patentbrief.org/inventor/adrian-bot"
    },
    {
      "name": "William GO",
      "url": "https://patentbrief.org/inventor/william-go"
    },
    {
      "name": "Vicki Plaks",
      "url": "https://patentbrief.org/inventor/vicki-plaks"
    },
    {
      "name": "Szu-Ting CHOU",
      "url": "https://patentbrief.org/inventor/szu-ting-chou"
    }
  ],
  "times_cited": 0,
  "tags": [
    "biotech",
    "pharmaceutical",
    "gene_editing",
    "oncology",
    "immunology"
  ],
  "abstract": "The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient.",
  "url": "https://patentbrief.org/patent/us/12630603/chimeric-antigen-receptor-t-cell-therapy-12630603",
  "markdown_url": "https://patentbrief.org/patent/us/12630603/chimeric-antigen-receptor-t-cell-therapy-12630603/md",
  "google_patents_url": "https://patents.google.com/patent/US12630603",
  "relatedPatents": [
    {
      "patentNumber": "12600775",
      "countryCode": "US",
      "title": "Treating a Specific Lymphoma with Modified T Cells",
      "url": "https://patentbrief.org/patent/us/12600775/chimeric-antigen-receptor-t-cell-therapy"
    },
    {
      "patentNumber": "9328156",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Attack Cancer",
      "url": "https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer"
    },
    {
      "patentNumber": "9481728",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Fight CD19 Cancers",
      "url": "https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer"
    },
    {
      "patentNumber": "12564648",
      "countryCode": "US",
      "title": "Gene Editing T-Cells to Fight CD7 Blood Cancers",
      "url": "https://patentbrief.org/patent/us/12564648/gene-editing-of-car-t-cells-for-the-treatment-of-t-cell-malignancies-with-chimer"
    },
    {
      "patentNumber": "12163952",
      "countryCode": "US",
      "title": "Predicting and Treating Dangerous Side Effects in CAR T-Cell Therapy",
      "url": "https://patentbrief.org/patent/us/12163952/determining-toxicity-risk-in-car-t-cell-therapy"
    }
  ]
}